Cryo-Cell International (NYSEAMERICAN:CCEL) Share Price Passes Above 200 Day Moving Average – Here’s Why

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.62 and traded as high as $3.68. Cryo-Cell International shares last traded at $3.62, with a volume of 2,605 shares.

Cryo-Cell International Price Performance

The business’s fifty day moving average price is $3.43 and its 200-day moving average price is $3.62. The stock has a market capitalization of $29.18 million, a price-to-earnings ratio of -10.97 and a beta of 0.49.

Cryo-Cell International (NYSEAMERICAN:CCEL) last released its quarterly earnings results on Tuesday, April 14th. The company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $7.68 million for the quarter.

Institutional Investors Weigh In On Cryo-Cell International

A hedge fund recently bought a new stake in Cryo-Cell International stock. Susquehanna International Group LLP acquired a new position in shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned about 0.14% of Cryo-Cell International at the end of the most recent reporting period. 10.44% of the stock is owned by hedge funds and other institutional investors.

About Cryo-Cell International

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.